NCT03144648 PRECAMA: Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women
| NCT ID | NCT03144648 |
| Status | Recruiting |
| Phase | — |
| Sponsor | International Agency for Research on Cancer |
| Condition | Breast Cancer Female |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2012-10-12 |
| Primary Completion | 2025-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2012-10-12 with a primary completion date of 2025-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Breast cancer has become a major public health problem in Latin America, as it is the most common form of cancer among women. Women are more likely to develop breast cancer at younger age, and to be diagnosed at an advanced stage compared to western women. Over the past twenty years, the mortality from breast cancer in Latin America has also been increasing very rapidly, and is currently the leading cause of cancer mortality. Little is known on specific risk factors for premenopausal breast cancer in general, and in Latin America in particular. There is a lack of specific knowledge on tumor molecular and pathological characteristics of breast cancer in Latin America premenopausal women, and this has major consequences on cancer treatment and survival. To improve our understanding on determinants of breast cancer incidence and mortality in young Latin America women and support preventive actions, we implemented an international, population-based multi-center study in Latin America: the PRECAMA study (Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women (PRECAMA): a multicenter population-based case-control study). PRECAMA is coordinated by the International Agency for Research on Cancer (IARC), and is conducted within 4 Latin American countries: Mexico, Costa Rica, Colombia and Chile. Major aims of the project are the following: 1. To develop a multi-centric population-based case-control study on breast cancer in premenopausal women in several countries in Latin America with structured collection of individual, clinical, pathological information and biological specimens, according to strictly controlled protocols 2. To characterize, in these populations, the subtypes of premenopausal breast cancer on the basis of their molecular and pathological phenotypes 3. To improve the identification of specific endogenous/exogenous factors, and disentangle the interplay of these different factors with regard to breast tumor subtypes. 4. Provide advanced training, induce a structuring effect on the breast cancer research community in Latin America and influence the public health agenda regarding the management of breast cancer. The results of our study will be of utmost importance to understand the etiology of breast cancer in Latin America countries, and would provide important information on the role of modifiable exposures for breast cancer prevention.
Eligibility Criteria
Inclusion Criteria: * woman between 20 and 45 years old * woman less than 3 years older or younger than the case * living in the area that the study is taking place during the past 3 years * woman menstruated at least once in the past 12 months * woman diagnosed with a primary breast cancer by histopathological examination (only for cases) Exclusion Criteria: * woman receiving tumor treatment, such as radiotherapy, chemotherapy or anti-estrogens (for example, tamoxifen) (except treatment for non-melanoma skin cancers) * woman taking (or has previously taken) any of the following medications in the past 6 months: tamoxifen, Evista (raloxifene), Fareston (toremifene), Aromasin (exemestane), Femara (letrozole), Arimidez (anastrozole) or Megace (megestrol) * woman suffering from chronic kidney failure * woman having a pathology that will hinder adequate communication * woman who is pregnant or nursing * woman who has been previously diagnosed with a cancer(except for non-melanoma skin cancers) * any other reason to exclude
Contact & Investigator
Sabina Rinaldi, PhD
PRINCIPAL INVESTIGATOR
International Agency for Research on Cancer, Lyon, France
Frequently Asked Questions
Who can join the NCT03144648 clinical trial?
This trial is open to female participants only, aged 20 Years or older, up to 45 Years, studying Breast Cancer Female. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03144648 currently recruiting?
Yes, NCT03144648 is actively recruiting participants. Contact the research team at rinaldis@iarc.who.int for enrollment information.
Where is the NCT03144648 trial being conducted?
This trial is being conducted at Barretos, Brazil, Santiago, Chile, Santiago, Chile, Santiago, Chile and 9 additional locations.
Who is sponsoring the NCT03144648 clinical trial?
NCT03144648 is sponsored by International Agency for Research on Cancer. The principal investigator is Sabina Rinaldi, PhD at International Agency for Research on Cancer, Lyon, France. The trial plans to enroll 3,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.